淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展

doi:10.12114/j.issn.1007-9572.2021.00.600

中国全科医学 ›› 2021, Vol. 24 ›› Issue (23): 2992-2997.DOI: 10.12114/j.issn.1007-9572.2021.00.600

淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展

杨婧诗1，邹立群2*

1.610041四川省成都市，四川大学华西临床医学院
2.610041四川省成都市，四川大学华西医院肿瘤一科
*通信作者：邹立群，教授，主任医师； E-mail：hxlcyxy@163.com

出版日期:2021-08-15 发布日期:2021-08-15

New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism　

YANG Jingshi1，ZOU Liqun2*

1. West China School of Medicine，Sichuan University，Chengdu 610041，China
2. No.1 Department of Oncology，West China Hospital，Sichuan University，Chengdu 610041，China
*Corresponding author：ZOU Liqun，Professor，Chief physician；E-mail：hxlcyxy@163.com

Published:2021-08-15 Online:2021-08-15

摘要/Abstract

摘要： 静脉血栓（VTE）是恶性肿瘤的常见并发症，亦是导致肿瘤患者死亡的第二位非肿瘤致死因素。淋巴瘤是VTE发病率较高的肿瘤之一，然而，目前针对淋巴瘤相关VTE风险的危险因素以及防治方法尚未达到一致共识。因此，本文将结合最新指南及文献总结，将淋巴瘤相关VTE的影响因素及预测模型作一综述，分别介绍与淋巴瘤疾病本身、临床检验指标以及抗肿瘤治疗相关的VTE危险因素。同时，将4种VTE预测模型（即：Khorana评分、Ottawa评分、Michigan评分以及ThroLy评分）对淋巴瘤VTE风险的预测价值进行分析，为淋巴瘤相关VTE的防治提供新的指导。

关键词: 淋巴瘤, 静脉血栓, 影响因素, 预后模型, 综述

Abstract: Venous thromboembolism（VTE）is a common complication，and the second leading non-cancer cause of death in cancer patients. Lymphoma is a type of cancer with a high incidence of VTE. However，there is no consensus on the risk factors and prevention methods for lymphoma-associated VTE. To provide the latest guidance on the prevention and treatment of lymphoma-associated VTE，in reviewing the recent guidelines and literature，we overviewed the influencing factors of lymphoma-associated VTE，including types and treatment of lymphoma，clinical laboratory indicators and anti-tumor therapies. Besides that，we also summarized and analyzed the recently developed risk prediction models for lymphoma-associated VTE，including the Khorana Risk Score，Ottawa Score，Michigan Risk Score and ThroLy Lymphoma Score.

Key words: Lymphoma, Venous thromboembolism, Influence factors, Prognostic model, Review

杨婧诗,邹立群. 淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展[J]. 中国全科医学, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.
YANG Jingshi,ZOU Liqun. New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism　[J]. Chinese General Practice, 2021, 24(23): 2992-2997. DOI: 10.12114/j.issn.1007-9572.2021.00.600.

参考文献

［1］TIMP J F，BRAEKKAN S K，VERSTEEG H H，et al. Epidemiology of cancer-associated venous thrombosis［J］. Blood，2013，122（10）：1712-1723. DOI：10.1182/blood-2013-04-460121.
［2］KHORANA A A，KUDERER N M，CULAKOVA E，et al. Development and validation of a predictive model for chemotherapy-associated thrombosis［J］. Blood，2008，111（10）：4902-4907. DOI：10.1182/blood-2007-10-116327.
［3］ANTIC D，MILIC N，NIKOLOVSKI S，et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients［J］. Am J Hematol，2016，91（10）：1014-1019. DOI：10.1002/ajh.24466.
［4］YOKOYAMA K. Thrombosis in lymphoma patients and in myeloma patients［J］. Keio J Med，2015，64（3）：37-43. DOI：10.2302/kjm.2014-0017-RE.
［5］KEKRE N，CONNORS J M. Venous thromboembolism incidence in hematologic malignancies［J］. Blood Rev，2019，33：24-32. DOI：10.1016/j.blre.2018.06.002.
［6］GOLDSCHMIDT N，LINETSKY E，SHALOM E，et al. High incidence of thromboembolism in patients with central nervous system lymphoma［J］. Cancer，2003，98（6）：1239-1242. DOI：10.1002/cncr.11623.
［7］BYUN J M，HONG J，YOON S S，et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy［J］. Thromb Res，2019，183：131-135. DOI：10.1016/j.thromres.2019.10.002.
［8］ZHOU X，TEEGALA S，HUEN A，et al. Incidence and risk factors of venous thromboembolic events in lymphoma［J］. Am J Med，2010，123（10）：935-941. DOI：10.1016/j.amjmed.2010.05.021.
［9］FARGE D，BOUNAMEAUX H，BRENNER B，et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer［J］. Lancet Oncol，2016，17（10）：e452-466. DOI：10.1016/S1470-2045（16）30369-2.
［10］AY C，VORMITTAG R，DUNKLER D，et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer：results from the Vienna Cancer and Thrombosis Study［J］. J Clin Oncol，2009，27（25）：4124-4129. DOI：10.1200/JCO.2008.21.7752.
［11］LEKOVIC D，MILJIC P，MIHALJEVIC B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma［J］. Thromb Res，2010，126（6）：477-480. DOI：10.1016/j.thromres.2010.08.017.
［12］SAMUELSON BANNOW B T，KONKLE B A. Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies：a review［J］. Thromb Res，2018，163：138-145. DOI：10.1016/j.thromres.2018.01.037.
［13］NEGAARD H F S，IVERSEN P O，?STENSTAD B，et al. Hypercoagulability in patients with haematological neoplasia：no apparent initiation by tissue factor［J］. Thromb Haemost，2008，99（6）：1040-1048. DOI：10.1160/TH07-09-0541.
［14］RUPA-MATYSEK J，GIL L，BARANSKA M，et al. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma［J］. Oncotarget，2018，9（30）：21190-21200. DOI：10.18632/oncotarget.25002.
［15］RUPA-MATYSEK J，GIL L，KROLL-BALCERZAK R，et al. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma［J］. Hematol Oncol，2017，35（4）：456-464. DOI：10.1002/hon.2321.
［16］RIEDL J，KAIDER A，REITTER E M，et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study（CATS）［J］. Thromb Haemost，2014，111（4）：670-678. DOI：10.1160/TH13-07-0603.
［17］YILDIZ A，ALBAYRAK M，PALA ?，et al. The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients：a 9-year single-center experience ［J］. J Oncol Pharm Pract，2020，26（2）：386-396. DOI：10.1177/1078155219851540.
［18］LI J S，TIAN X D，WANG M J，et al. A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis［J］. Onco Targets Ther，2018，11：9007-9011. DOI：10.2147/OTT.S183298.
［19］PARK H，KIM J W，YOUK J，et al. Serum free light chain difference and β2 microglobulin levels are risk factors for thromboembolic events in patients with AL amyloidosis［J］. Clin Lymphoma Myeloma Leuk，2018，18（6）：408-414. DOI：10.1016/j.clml.2018.03.005.
［20］RUPA-MATYSEK J，GIL L，KAZMIERCZAK M，et al. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies：validation of the Khorana Risk Score［J］. Med Oncol，2017，35（1）：5. DOI：10.1007/s12032-017-1065-4.
［21］JACCARD A，GACHARD N，MARIN B，et al. Efficacy of L-asparaginase with methotrexate and dexamethasone（AspaMetDex regimen）in patients with refractory or relapsing extranodal NK/T-cell lymphoma，a phase 2 study［J］. Blood，2011，117（6）：1834-1839. DOI：10.1182/blood-2010-09-307454.
［22］DE STEFANO V，ZA T，CIMINELLO A，et al. Haemostatic alterations induced by treatment with asparaginases and clinical consequences［J］. Thromb Haemost，2015，113（2）：247-261. DOI：10.1160/TH14-04-0372.
［23］LEE J H，LEE J，YHIM H Y，et al. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea［J］. J Thromb Haemost，2017，15（4）：655-661. DOI：10.1111/jth.13636.
［24］SANFILIPPO K M，WANG T F，GAGE B F，et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma［J］. Thromb Res，2016，143：86-90. DOI：10.1016/j.thromres.2016.05.008.
［25］ZANGARI M，SIEGEL E，BARLOGIE B，et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide：implications for therapy［J］. Blood，2002，100（4）：1168-1171. DOI：10.1182/blood-2002-01-0335.
［26］PAREDES N，XU L，BERRY L R，et al. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces［J］. Br J Haematol，2003，120（2）：315-324. DOI：10.1046/j.1365-2141.2003.03971.x.
［27］DAVID R J，BARAN A，LOH K P，et al. Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma［J］. Clin Lymphoma Myeloma Leuk，2018，18（12）：781-787. DOI：10.1016/j.clml.2018.08.014.
［28］ARORA M，GOWDA S，TUSCANO J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma［J］. Ther Adv Hematol，2016，7（4）：209-221. DOI：10.1177/2040620716652861.
［29］NOWAKOWSKI G S，LAPLANT B，MACON W R，et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma：a phase Ⅱstudy［J］. J Clin Oncol，2015，33（3）：251-257. DOI：10.1200/JCO.2014.55.5714.
［30］ALBERTSSON-LINDBLAD A，KOLSTAD A，LAURELL A，et al.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma［J］. Blood，2016，128（14）：1814-1820. DOI：10.1182/blood-2016-03-704023.
［31］NOWAKOWSKI G S，LAPLANT B，HABERMANN T M，et al. Lenalidomide can be safely combined with R-CHOP（R2CHOP）in the initial chemotherapy for aggressive B-cell lymphomas：phase I study［J］. Leukemia，2011，25（12）：1877-1881. DOI：10.1038/leu.2011.165.
［32］PAL R，MONAGHAN S A，HASSETT A C，et al. Immunomodulatory derivatives induce PU. 1 down-regulation，myeloid maturation arrest，and neutropenia［J］. Blood，2010，115（3）：605-614. DOI：10.1182/blood-2009-05-221077.
［33］YAMSHON S，CHRISTOS P J，DEMETRES M，et al. Venous thromboembolism in patients with B-cell non-hodgkin lymphoma treated with lenalidomide：a systematic review and meta-analysis［J］. Blood Adv，2018，2（12）：1429-1438. DOI：10.1182/bloodadvances.2018016683.
［34］KEY N S，KHORANA A A，KUDERER N M，et al. Venous thromboembolism prophylaxis and treatment in patients with cancer：ASCO clinical practice guideline update［J］. J Clin Oncol，2020，38（5）：496-520. DOI：10.1200/JCO.19.01461.
［35］SANTI RM，CECCARELLI M，BERNOCCO E，et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi（FIL）［J］. Thromb Haemost，2017，10.1160/TH16-11-0895. DOI：10.1160/TH16-11-0895.
［36］HOHAUS S，TISI M C，BARTOLOMEI F，et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization［J］. Blood Cancer J，2018，8（6）：54. DOI：10.1038/s41408-018-0096-1.
［37］LOUZADA M L，CARRIER M，LAZO-LANGNER A，et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism［J］. Circulation，2012，126（4）：448-454. DOI：10.1161/CIRCULATIONAHA.111.051920.
［38］DEN EXTER P L，KOOIMAN J，HUISMAN M V. Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis［J］. J Thromb Haemost，2013，11（5）：998-1000. DOI：10.1111/jth.12192.
［39］ALATRI A，MAZZOLAI L，FONT C，et al. Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry［J］. Thromb Haemost，2017，117（8）：1630-1636. DOI：10.1160/TH17-02-0116.
［40］CHOPRA V，KAATZ S，CONLON A，et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis［J］. J Thromb Haemost，2017，15（10）：1951-1962. DOI：10.1111/jth.13794.
［41］LUND J L，?STG?RD L S，PRANDONI P，et al. Incidence，determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark［J］. Thromb Res，2015，136（5）：917-923. DOI：10.1016/j.thromres.2015.09.001.
［42］JASTI N，STREIFF M B. Prevention and treatment of thrombosis associated with central venous catheters in cancer patients［J］. Expert Rev Hematol，2014，7（5）：599-616. DOI：10.1586/17474086.2014.954541.
［43］RUPA-MATYSEK J，BRZEZNIAKIEWICZ-JANUS K，GIL L，et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice ［J］. Cancer Med，2018，7（7）：2868-2875. DOI：10.1002/cam4.1540.
［44］KHORANA A A，FRANCIS C W，CULAKOVA E，et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy ［J］. J Thromb Haemost，2007，5（3）：632–634. DOI：10.1111/j.1538-7836.2007.02374.x.
［45］MAHAJAN A，BRUNSON A，WHITE R，et al. The epidemiology of cancer-associated venous thromboembolism：an update［J］. Semin Thromb Hemost，2019，45（4）：321-325. DOI：10.1055/s-0039-1688494.

[1]	闫梓薇, 聂佳桦, 石妍, 魏立民. 白蛋白/γ-谷氨酰转移酶比值与2型糖尿病合并代谢相关脂肪性肝病的相关性研究[J]. 中国全科医学, 2026, 29(30): 4431-4437.
[2]	孙秀芹, 冯振龙, 魏兰萱, 曾宇欣, 刘金波, 马林, 安占天, 王宏宇. 北京市石景山区中老年居民代谢综合征患病现状及行为生活方式影响因素研究[J]. 中国全科医学, 2026, 29(30): 4424-4430.
[3]	王思雪, 袁越, 熊丽莎, 周纯祎, 袁项青, 方雪莲, 张艾琳, 王云翠. 中医健康行为阶段性影响因素量表的编制及信效度检验[J]. 中国全科医学, 2026, 29(29): 4337-4344.
[4]	黄嘉婷, 柳玲娜, 宁艳花, 史晶, 李欣锦, 杨彩玲, 姚静. 农村老年人家庭医生签约服务的表达需要和感知需要一致性：对宁夏回族自治区456名常住居民的问卷调查[J]. 中国全科医学, 2026, 29(29): 4217-4225.
[5]	黎婉钰, 金花, 张倩倩, 于德华. 上海市社区全科医生实施主动健康管理知信行现状及其影响因素[J]. 中国全科医学, 2026, 29(28): 4157-4163.
[6]	张帆, 常建华, 杨娟, 乔慧, 谢永鑫. 宁夏回族自治区农村居民慢性病共病的流行趋势及关联规则分析[J]. 中国全科医学, 2026, 29(27): 3956-3968.
[7]	付梦茹, 薛梅启旸, 蒋雨桐, 陈鸣声, 钱东福, 李忠. 农村心房颤动患者自我管理能力影响因素研究[J]. 中国全科医学, 2026, 29(27): 3947-3955.
[8]	王稼璇, 王兆娴, 黄小芬, 赵进奎, 拉巴桑珠. 2004—2023年中国登革热时空分布特征与影响因素研究[J]. 中国全科医学, 2026, 29(26): 3844-3850.
[9]	焦姝婷, 井浩然, 赵亚利. 北京市城区社区就诊老年患者慢性瘙痒症状强度及影响因素研究[J]. 中国全科医学, 2026, 29(25): 3655-3663.
[10]	陈龙, 胡伟, 叶兵. 广东省居民门诊就医选择及其影响因素：基于2023年第七次全国卫生服务调查数据的分析[J]. 中国全科医学, 2026, 29(25): 3608-3613.
[11]	杨智凯, 袁蓓蓓. 基层医疗卫生机构运行环境和机构特征与其服务利用量的关系：基于整合证据和案例地区实证数据寻找潜在干预点[J]. 中国全科医学, 2026, 29(25): 3584-3592.
[12]	倪一丹, 王莹, 朱瑜可, 徐静, 王丽. 社区老年人功能性体适能水平潜在剖面及影响因素研究[J]. 中国全科医学, 2026, 29(24): 3493-3499.
[13]	裴如青, 周郁秋, 张思宇, 刘西俊. 中国精神分裂症患者复发影响因素的Meta分析[J]. 中国全科医学, 2026, 29(23): 3359-3370.
[14]	林子娜, 崔梁瑜, 井天月, 刘大胜, 赵学尧, 韩学杰, 王丽颖. 国内外指南制定方法学手册中临床问题提出方法与影响因素分析[J]. 中国全科医学, 2026, 29(23): 3342-3350.
[15]	刘迪, 李琨, 胡丙杰, 石磊. 基于模糊集定性比较分析的社区卫生服务人员工作绩效的驱动因素与提升路径研究[J]. 中国全科医学, 2026, 29(22): 3116-3122.

淋巴瘤相关静脉血栓的影响因素及风险评估模型的研究进展

New Progression in Influencing Factors and Risk Prediction Models for Lymphoma-associated Venous Thromboembolism

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

留言